Background-Hypertension treatment guidelines recommend that blood pressure (BP) be lowered to Ͻ140/90 mm Hg, but that a reduction to Ͻ130/80 mm Hg be adopted in patients at high cardiovascular (CV) risk. We investigated the CV and renal benefits associated with these BP targets in the high-CV-risk population of the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Methods and Results-Patients were divided into 4 groups according to the proportion of in-treatment visits before the occurrence of an event (Ͻ25%-Ͼ75%) in which BP was reduced to Ͻ140/90 or Ͻ130/80 mm Hg. After adjustment for demographic and clinical variables, a progressive increase in the proportion of visits in which BP was reduced to Ͻ140/90 or Ͻ130/80 mm Hg was associated with a progressive reduction in the risk of stroke, new onset of microalbuminuria or macroalbuminuria, and return to normoalbuminuria in albuminuric patients. An increased frequency of BP control to either target did not have any consistent effect on the adjusted risk of myocardial infarction and heart failure. The adjusted risk of CV events was reduced by increasing the frequency of BP control to Ͻ140/90 mm Hg, but not to Ͻ130/80 mm Hg. Similar findings were obtained for the achievement of the BP target in the visit preceding a CV event. Conclusion-The more frequent achievement of the BP targets recommended by guidelines led to cerebrovascular and renal protection, but did not increase cardiac protection. Overall, CV protection was favorably affected by the less tight but not by the tighter BP target. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00153101. ; and Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.).
H ypertension treatment guidelines emphasize that lowering blood pressure (BP) reduces cardiovascular (CV) events in virtually all clinical conditions in which BP is elevated. [1] [2] [3] They also recommend different BP targets according to the level of total CV risk, [2] [3] [4] [5] ie, to Ͻ140/90 mm Hg (systolic/diastolic) in the general hypertensive population (including the elderly, in whom hypertension is particularly common 6 ), but to Ͻ130/80 mm Hg in those at high CV risk because of diabetes mellitus, renal disease, or a prior CV event.
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Although the association between BP reduction from above-normal initial values and CV risk has been documented in a large number of randomized trials, 7-9 the scientific basis for the guideline recommendations to lower BP to Ͻ140/90 or 130/80 mm Hg has been questioned recently on 3 grounds. 10, 11 First, in trials of elderly hypertensive patients, the systolic BP (SBP) values of the actively treated group almost invariably remained Ͼ140 mm Hg. Second, in trials of patients with a history of CV disease, reducing SBP to Ͻ130 mm Hg has usually not shown an additional reduction of CV events compared with BP remaining at values Ͼ130 mm Hg. Third, this was also the case in trials that addressed the question of the optimal BP target in patients with diabetes mellitus. In these patients, a recent trial has shown that the overall risk of CV events was similar in diabetic patients randomized to an in-treatment SBP of Ͻ140 or Ͻ120 mm Hg, although the latter group showed a 3-timesgreater incidence of serious side effects. 12 Furthermore, a post hoc analysis of hypertensive diabetic patients with a history of coronary disease reported that CV events decreased when SBP was reduced from Ͼ140 mm Hg to between 130 and 140 mm Hg, but that no further benefit, or even harm, occurred when values Ͻ130 mm Hg were achieved. 13 A post hoc analysis of the large database provided by the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET) trial of high-CV-risk patients has recently shown that in patients with high initial BP values, BP reduction was associated with a reduction in the incidence of CV morbid or fatal events but that the CV benefit was less evident or even absent when the initial BP values were in the high-normal or normal range. 14 The purpose of the present analysis was to provide further information on this issue by focusing on the CV effects of achieving or not achieving the target BP values specifically recommended by guidelines, ie, Ͻ140/90 or Ͻ130/ 80 mm Hg. The results cast further doubt on the ability of the lower BP targets to reduce CV risk, and suggest that more evidence is needed from prospective randomized trials to establish the BP target that can optimally protect individuals at high CV risk.
Methods

Design, Objectives, and End Points
The design, treatment algorithms, and results of ONTARGET have been reported previously. 15 Briefly, ONTARGET was a multicenter trial that enrolled patients with known atherosclerotic disease (myocardial infarction, stroke, peripheral artery disease, and cardiac revascularization procedures) or diabetes mellitus with end-organ damage. Patients with a history of heart failure, an SBP Ͼ160 mm Hg, or a diastolic BP (DBP) Ͼ100 mm Hg were excluded. After a single-blind run-in period, patients were randomized to take telmisartan once daily, ramipril once daily, or both. After titration, the doses of telmisartan and ramipril were 80 and 10 mg daily, respectively. Treatments were continued in a double-blind fashion for a median follow-up of 56 months, during which visits occurred at 6 weeks, 6 months, and then every 6 months. The main objectives of the trial were to determine whether the CV protection offered by telmisartan and the combination of telmisartan and ramipril was noninferior or superior, respectively, to that offered by ramipril alone. The primary end point of the trial was the composite outcome of death resulting from CV causes, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure. Main secondary end points were the composite outcome of the first 3 events (ie, without heart failure) and the incidence of the specific CV events included in the composite outcome. Other secondary end points were renal events that consisted of end-stage renal disease (initiation of dialysis, need for renal transplantation, or doubling of serum creatinine), new onset of microalbuminuria, new onset of macroalbuminuria, and return to normoalbuminuria from initial macroalbuminuria or microalbuminuria. New onset of microalbuminuria and macroalbuminuria was defined as a urine albumin-to-creatinine ratio Ն30 and Ն300 mg/g, respectively, in a morning urine sample. Because the primary outcome was not different between the 3 treatment groups, they were pooled. Four groups of patients were considered according to the percentage of in-treatment visits in which BP was found to be controlled: Ͻ25%, 25% to 49%, 50% to 74%, and Ն75%, taking only patients in whom Ն7 visits were available before the occurrence of an end point. The number of 7 visits was set because, for purely technical reasons, the chance of falling into 1 of the 4 groups is grossly imbalanced when very few visits are available, which may introduce bias. From guideline recommendations, 1-3 BP control was defined as a value Ͻ140/90 or Ͻ130/80 mm Hg. When the higher BP target was used, we included all patients with a prerandomization baseline SBP Ն140 mm Hg; for the lower BP target, we included all patients with a baseline SBP Ն130 mm Hg.
Several types of analysis were done. In the first, the incidence of each end point was calculated in percent. In the second, the relative risk of an end point was quantified by the Cox proportional hazard model, taking the group with Ն75% of the visits with BP under control as reference. Hazard ratios were adjusted for potential baseline confounders, ie, age, sex, SBP and DBP, heart rate, body mass index, lipid profile, blood glucose, smoking, alcohol consumption, diabetes mellitus, history of CV events, and treatment type. In the third, the risk of an end point was analyzed by including in the Cox regression model whether BP had or had not been controlled to the higher or lower target values in a time-dependent fashion, ie, by considering the BP values in the visit immediately preceding the occurrence of the end point. Data were adjusted for the confounding variables mentioned above.
Finally, a logistic regression model was used to identify baseline demographic and clinical characteristics that predicted the most consistent achievement of the less tight or tighter BP target using all patients with a baseline SBP Ն140 mm Hg (nϭ14 494) and Ն130 mm Hg (nϭ19 631), respectively. The contribution of each baseline factor was assessed after adjustment for all other remaining factors. Data are shown as percentage, meanϮSD, or 95% confidence intervals. A value of PϽ0.05 was taken to be statistically significant. Table 1 shows the prerandomization characteristics of the patients with a baseline SBP Ն140 mm Hg in whom BP was subsequently lowered to Ͻ140/90 mm Hg in Ͻ25%, 25% to 49%, 50% to 74%, and Ն75% of the visits made before the occurrence of an end point (nϭ12 554 -11 782, depending on the time of the end-point occurrence). Some characteristics (age, DBP, high-density lipoprotein cholesterol, heart rate, and serum creatinine) were similar, whereas others differed between groups. The most important differences were a higher baseline SBP in groups in which BP control was less frequent, and small increases in low-density lipoprotein cholesterol, blood glucose, and a history of diabetes mellitus in the group with the most frequent to the group with the least frequent BP control. Figure 1 shows the incidence of CV events and the average in-treatment BP in the 4 groups. The mean in-treatment SBP and DBP (pre-end-point values) were progressively lower from the group with the lowest to the group with the highest percentage of visits in which BP was Ͻ140/90 mm Hg. The incidence of the primary end point, the 3-fold end point of CV death, heart failure, and stroke, decreased progressively from the group with the lowest to the group with the highest frequency of BP control. No such trend was seen for myocardial infarction, which showed a reduced incidence only in the group with the most frequent BP control.
Results
CV Events and Risk for a BP Target <140/90 mm Hg
Table 2 (left) shows the hazard ratios for CV events after adjustment for differences in baseline values (see Methods). The adjusted risk of myocardial infarction, heart failure, and CV mortality showed no unfavorable trend as the rate of BP control to Ͻ140/90 mm Hg decreased. This was not the case for stroke, the primary end point, and to a lesser extent the 3-fold end point, which showed a progressive significant increase in the adjusted risk as the BP control rate went from Ն75% to Ͻ25% of the visits.
CV Events and Risk for a BP Target <130/80 mm Hg
The prerandomization characteristics of patients with a baseline SBP Ն130 mm Hg (nϭ17 087-16 109, depending on the time of the end-point occurrence) in whom BP was subsequently lowered to Ͻ130/80 mm Hg in Ͻ25%, 25% to 49%, 50% to 74%, and Ն75% of the visits are presented in the online-only Data Supplement. The between-group differences were similar to those described in Table 1 .
As shown in Figure 2 , achieving the lower BP target was more frequently associated with a progressively lower mean in-treatment SBP and DBP (pre-end-point values) and with a progressive reduction in the incidence of the primary end point, the 3-fold end point, CV mortality, and stroke, for which the reduction was particularly steep. No such trend was seen for myocardial infarction and heart failure, however. Furthermore, as shown in Table 2 (right), not only for cardiac events but also for the primary end point, the 3-fold end point, and CV mortality, the adjusted hazard ratio did not show any unfavorable trend from the most to the least frequent rate of BP control to the lower target. An exception was stroke; the adjusted hazard ratio for stroke showed a significant and BP indicates blood pressure; HR, hazard ratio; CI, confidence interval; and CV, cardiovascular. Adjustment was made for age, sex, smoking, alcohol consumption, body mass index, baseline systolic (SBP) and diastolic BP, heart rate, lipid variables, blood glucose, serum creatinine, history of myocardial infarction, history of stroke, history of diabetes mellitus, and treatment type. Data on BP target Ͻ140/90 mm Hg refer to patients with baseline SBP of Ն140 mm Hg (n between 11 782 and 12 554). Data on BP target of Ͻ130/80 mm Hg refer to patients with baseline SBP Ն130 mm Hg (n between 16 109 and 17 087). Circulation October 18, 2011 marked increase as the frequency of BP control to the lower target decreased. Table 3 shows the results of the time-dependent analysis that related end points to the presence or absence of BP control at the visit immediately preceding an event. BP control to Ͻ140/90 or Ͻ130/80 mm Hg did not have any significant impact on the hazard ratios for myocardial infarction and heart failure. The unadjusted and the adjusted hazard ratios for the primary end point, the 3-fold end point, CV mortality, and stroke showed a significant risk reduction in patients when the preceding visit BP was controlled to Ͻ140/ 90 mm Hg. This was not the case with the achievement of the BP goal of Ͻ130/80 mm Hg, which was associated only with a reduction of risk for stroke, albeit not significant for the adjusted risk. In addition, BP control to Ͻ140/90 or 13/ 80 mm Hg did not have a significant effect on myocardial infarction when patients were dichotomized by taking 75% of the visits under control as the cutoff value (Pϭ0.064 and 0.423, respectively).
Time-Dependent Analysis
Renal Events at Different BP Targets
As shown in Figure 3 , the incidence of renal events decreased progressively from the group with the lowest to the group with the highest rate of BP control, regardless of whether the higher or the lower target BP values were used. With the exception of the doubling of serum creatinine and end-stage renal disease, this was the case also after adjustment for baseline differences (Figure 4 ). That is, from the more frequent to the less frequent rate of less tight or tighter BP control, there was a progressive increase in the risk of new onset of microalbuminuria and macroalbuminuria, with the chance of returning to normoalbuminuria in those with initial albuminuria showing a progressive reduction.
Factors Favoring or Opposing Achievement of BP Targets
The factors involved in the probability of more frequently achieving less tight or tighter BP target are shown in Figure  5 . For either target, achieving BP control was significantly more likely when treatment was based on telmisartan or the combination of telmisartan and ramipril compared with ramipril alone. Asian ethnicity, smoking, and a history of myocardial infarction also favored BP control, which was made less likely by older age, female sex, black ethnicity, obesity, diabetes mellitus, and a history of cerebrovascular events. Asian ethnicity and diabetes mellitus were the single most important favorable and unfavorable factors, respectively; the former increased the chance of achieving BP control by Ϸ40%, whereas diabetes mellitus reduced it by 30%.
Discussion
In the large number of high-CV-risk patients of the ONTAR-GET trial, a higher rate of BP control to the values recommended by guidelines (Ͻ140/90 and Ͻ130/80 mm Hg) had complex effects on the risk of CV events. First, after adjustment for demographic and clinical variables, the risk of stroke showed a marked progressive reduction from the less to the more frequent achievement of either the less tight or the tighter BP target. Second, the adjusted risk of myocardial infarction and congestive heart failure was inconsistently affected by the different rates of BP control to both the less tight and the tighter BP target. Third, the adjusted risk of overall CV events was favorably affected by a more frequent achievement of the less tight BP target (Ͻ140/90 mm Hg), whereas lesser or greater rates of the Ͻ130/80 mm Hg target made little difference; this was also the case for the adjusted risk of CV mortality. These results cast doubt on the widespread perception that to maximize CV protection, physicians should pursue aggressive BP control (Ͻ130/80 mm Hg) when patients have a high CV risk, a concept reflected by current guidelines. [2] [3] [4] [5] In the high-CV-risk patients of ONTARGET, it appears that this may have beneficial effects for stroke, but not for myocardial infarction, heart failure, or overall CV events. It also appears that in high-CV-risk patients, overall CV protection may be better for the less tight BP target recommended by guidelines (Ͻ140/90 mm Hg), although even for Ͻ140/90 mm Hg we saw a difference between the clear-cut cerebrovascular event reduction and the inconsistent cardiac protection.
The present results are in line with previous observations on the effects of BP reduction on cardiac and cerebrovascular events, which have similarly reported that reducing SBP to Ͻ130 mm Hg has a protective effect on the incidence of stroke, whereas the incidence of other CV events remains unchanged or increased. 12, 14, 16, 17 In this context, 2 important findings are those obtained in the International Verapamil SR/Trandolapril Study (INVEST) 13 and Action to Control Cardiovascular Risk in Diabetes (ACCORD) 12 trial. In IN-VEST, 13 reducing SBP to Ͻ130 mm Hg did not carry any CV advantage for high-risk hypertensive patients with diabetes mellitus compared with achieving SBP values between 130 and 140 mm Hg. Indeed, the CV risk appeared to increase as achieved SBP was lowered to values well below 130 mm Hg. In the ACCORD trial, 12 also in diabetic hypertensive patients, a reduction of SBP to Ϸ119 mm Hg was associated with a reduction in the risk of stroke, but not of myocardial infarction or CV morbidity and mortality. Interestingly, the SBP value of 119 mm Hg that led to a reduction in stroke in ACCORD is similar to the in-treatment SBP value at which the maximal protective effect on stroke was seen in the present analysis, ie, 116 mm Hg. These values are also similar to those shown to be associated with the minimal level of stroke risk in observational studies. 17 This suggests that protection against stroke is generally governed by the lower the BP, the better rule. This rule also appears to apply to renal protection, because in the ONTARGET patients, in line with previous observations, 18, 19 a progressively greater rate of BP control was associated with a marked progressive benefit on a number of renal variables (eg, new-onset microalbuminuria and macroalbuminuria) of documented clinical significance 20 -25 ; this was also the case for both the less tight and the tighter BP targets. Indeed, the most frequent control to the lower BP target had such a favorable renal effect that it made Figure  3 . The group in which BP control was seen in Ն75% of the visits was taken as the reference. Adjustment was made for the prerandomization demographic and clinical variables mentioned in Methods and in Table 2 . ESRD indicates end-stage renal disease; SCr, serum creatinine. events such as new onset of macroalbuminuria almost indiscernible.
Our results do not clarify the reasons why the effects of a tighter BP control are different for the brain and the kidney compared with the heart. One possibility is that this betweenorgan disparity depends on the fact that in ONTARGET (and in some previous trials) the majority of the patients had a history of cardiac disease, given that disease may impair the ability of an organ to maintain blood flow at low-BP regimens. For the heart, this has been shown to occur in a study in which a DBP reduction to Ͻ90 mm Hg was associated with a coronary blood flow reduction in hypertensive patients with left ventricular hypertrophy, whereas in hypertensive individuals with a normal heart, coronary blood flow remained unchanged down to a DBP value of 70 mm Hg. 26 It should be emphasized, however, that in the Preventing Strokes By Lowering Blood Pressure in Patients With Cerebral Ischemia (PROGRESS) trial, patients with a history of cerebrovascular events showed a progressive reduction in the risk of recurrent stroke for achieved SBP values Ϸ120 mm Hg or below. 27 This favors an alternative hypothesis, ie, that the heart responds differently to treatment- induced BP reductions because of less pronounced ability to maintain its perfusion at lower BP values compared with the brain and the kidney, in which blood flow autoregulation is extremely effective over a wide BP range. 28, 29 Several other points deserve mention. First, an important new finding of the present study is that the effects on CV events of BP control, as calculated for many visits, were substantially reproduced by the time-dependent analysis that related the occurrence of an end point to BP control in the immediately preceding visit. This provides evidence in favor of the importance of stable BP control throughout the treatment period, in line with the results of post hoc analyses of a number of trials 30 -32 that have shown that, in treated hypertensive patients, BP instability may adversely affect CV risk, particularly stroke, independently of in-treatment average BP mean values. Second, the present study has the limitations of any post hoc analysis; ie, the effects of different BP targets were compared in nonrandomized groups of patients who differed in several baseline characteristics. Although adjustment for a large number of baseline demographic and clinical variables was used, we cannot entirely rule out the possibility that the results could be explained by factors other than the achieved BP.
Third, one may speculate on the implications of the differential effects of BP-lowering strategies on the brain and the heart in daily life. Adopting more aggressive BP lowering might be justified when the risk of stroke clearly exceeds that of a cardiac event. At a population level, this may be the case in Asian countries where stroke accounts for Ն80% of the overall CV events. 33 It may also be the case, however, in patients from Western countries with a history of a cerebrovascular event, in whom the risk of stroke recurrence is particularly high. 34, 35 In addition, aggressive BP control may also be considered in individuals with severe hypertension because the relative contribution of stroke to the overall incidence of CV events may be greater. This is probably what happened in the ONTARGET patients, in whom baseline SBP was Ն140 mm Hg and target BP was set at Ͻ140/ 90 mm Hg. Finally, the present analysis provides a comprehensive overview of the factors favoring or opposing achievement of BP control based on one of the largest available databases. It should be noted that, in line with previous reports, 36 the single most important factor that makes less tight or tighter BP control more difficult was found to be diabetes mellitus.
Conclusions
Our study provides evidence that in high-CV-risk patients a BP reduction to Ͻ140/90 mm Hg is associated with CV protection. Overall CV protection, however, may not be improved by lower BP targets, as recommended for higherrisk subjects in current guidelines.
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